T. Rowe Price US Equity Research ETF (TSPA)
- Previous Close
31.65 - Open
31.86 - Bid 30.00 x 1400
- Ask 35.02 x 1000
- Day's Range
31.84 - 31.95 - 52 Week Range
24.48 - 32.85 - Volume
55,141 - Avg. Volume
33,831 - Net Assets 169.77M
- NAV 31.86
- PE Ratio (TTM) --
- Yield 0.37%
- YTD Daily Total Return 8.43%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.34%
The fund will normally invest at least 80% of its assets in U.S. equity securities (or futures that have similar economic characteristics). The advisor attempts to create a portfolio with similar characteristics to the Standard & Poor’s 500 Stock Index® (index) with the potential to provide excess returns relative to the index. The fund will generally remain fully invested (less than 5% in cash reserves) and seeks to be sector neutral when compared to the index. The fund is non-diversified.
T. Rowe Price
Fund Family
Large Blend
Fund Category
169.77M
Net Assets
2021-06-08
Inception Date
Performance Overview: TSPA
Trailing returns as of 4/26/2024. Category is Large Blend.
People Also Watch
Holdings: TSPA
Top 10 Holdings (32.56% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: TSPA
Analyst Report: Monster Beverage Corporation
Monster Beverage is a leader in the energy drink subsegment of the nonalcoholic beverage market, generating two thirds of revenue in the US and Canada. The well-known Monster trademark includes brands such as Monster Energy, Monster Ultra, Java Monster, and Juice Monster. The firm also owns other energy drink brands, such as Reign, NOS, Burn, and Mother, and brews and distributes beers and flavored malt beverages following the acquisition of a craft brewer in 2022. Monster controls branding and innovation but outsources beverage manufacturing and packaging to copackers and finished goods distribution to bottlers in the global Coca-Cola system (pursuant to a 20-year agreement inked in 2015). Coke is the largest shareholder of Monster with a 19.5% stake.
RatingPrice TargetAnalyst Report: Monster Beverage Corporation
Monster Beverage is a leader in the energy drink subsegment of the nonalcoholic beverage market, generating two thirds of revenue in the US and Canada. The well-known Monster trademark includes brands such as Monster Energy, Monster Ultra, Java Monster, and Juice Monster. The firm also owns other energy drink brands, such as Reign, NOS, Burn, and Mother, and brews and distributes beers and flavored malt beverages following the acquisition of a craft brewer in 2022. Monster controls branding and innovation but outsources beverage manufacturing and packaging to copackers and finished goods distribution to bottlers in the global Coca-Cola system (pursuant to a 20-year agreement inked in 2015). Coke is the largest shareholder of Monster with a 19.5% stake.
RatingPrice TargetAnalyst Report: QUALCOMM Incorporated
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.
RatingPrice TargetAnalyst Report: CRISPR Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice Target